期刊
SCIENCE SIGNALING
卷 14, 期 706, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.abg4747
关键词
-
资金
- Alzheimer's Association [ZEN-17-438829]
- NIH [AG050431]
- Department of Veterans Affairs [1IK6 BX004982]
The combination of low-dose gemfibrozil and retinoic acid enhances the uptake and degradation of amyloid (A beta) in astrocytes through a PPAR alpha-dependent pathway, potentially offering a new therapeutic approach for Alzheimer's disease.
Astrocytes are a type of glial cell that are activated in the brain tissue of patients with Alzheimer's disease to induce the accumulation of amyloid (A beta). We previously found that a combination of low-dose gemfibrozil (GFB; a drug approved to treat high cholesterol) and retinoic acid (RA; a vitamin A derivative) induces lysosomal bio-genesis through peroxisome proliferator-activated receptor alpha (PPAR alpha)-mediated transcription of the gene encoding transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy. Here, we found that the same combination (GFB-RA) enhanced the uptake of A beta from the extracellular space and its subsequent degradation in astrocytes through a PPAR alpha-dependent pathway. GFB-RA stimulated the abundance of both low-density lipoprotein receptor (LDLR) and TFEB in astrocytes through PPAR alpha. LDLR was critical for A beta uptake, whereas TFEB was critical for its degradation. GFB-RA treatment also increased autophagic flux and lysosomal activity in astrocytes. Consistent with these effects and in a manner dependent on astroglial PPAR alpha, oral administration of GFB-RA switched astroglial activation to a neuroprotective state, lowered A beta burden in the brain, and improved spatial learning and memory in the 5XFAD mouse model of Alzheimer's disease. These findings uncover a new function of PPAR alpha in stimulating astroglial uptake and degradation of A beta and suggest possible repurposing of GFB-RA combination therapy for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据